<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.105124</article-id><article-id pub-id-type="publisher-id">ACM-35655</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200500000_82930092.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  HIF-1α、VEGF与肿瘤的侵袭和转移
  HIF-1α, VEGF and Tumor Invasion and Metastasis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>崔</surname><given-names>昌裕</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>05</issue><fpage>811</fpage><lpage>816</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肿瘤的侵袭和转移是极其复杂的过程，目前机制尚不明确，涉及了众多基因和信号通路。缺氧诱导因子-1α (HIF-1α)和血管内皮生长因子(VEGF)是该通路中重要的转录因子，它们通过各种机制深度参与肿瘤的侵袭和转移过程，包括参与缺氧条件下的血管生成及多种调控肿瘤侵袭和转移的信号通路，与患者的不良预后密切相关。本文旨在阐明HIF-1α和VEGF之间的相互作用和调节机制，以及在肿瘤侵袭和转移中可能的临床影响。
    Tumor invasion and metastasis is an extremely complex process; the mechanism is not clear, involving multiple genes and signal pathways. At present, hypoxia-inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) are important transcription factors. They are deeply involved in the process of tumor invasion and metastasis through various mechanisms, including angiogenesis under hypoxia and various signal pathways regulating tumor invasion and metastasis, which are closely related to the poor prognosis of patients. The purpose of this study is to clarify the interaction and regulatory mechanism between HIF-1α and VEGF, as well as the possible clinical effects on tumor invasion and metastasis. 
  
 
</p></abstract><kwd-group><kwd>缺氧诱导因子-1α，血管内皮生长因子，肿瘤, HIF-1α</kwd><kwd> VEGF</kwd><kwd> Tumor</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>HIF-1α、VEGF与肿瘤的侵袭和转移<sup> </sup></title><p>崔昌裕<sup>*</sup>，赵红<sup>#</sup></p><p>延安大学附属医院，陕西 延安</p><p>收稿日期：2020年5月1日；录用日期：2020年5月13日；发布日期：2020年5月20日</p><disp-formula id="hanspub.35655-formula43"><graphic xlink:href="//html.hanspub.org/file/19-1571309x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>肿瘤的侵袭和转移是极其复杂的过程，目前机制尚不明确，涉及了众多基因和信号通路。缺氧诱导因子-1α (HIF-1α)和血管内皮生长因子(VEGF)是该通路中重要的转录因子，它们通过各种机制深度参与肿瘤的侵袭和转移过程，包括参与缺氧条件下的血管生成及多种调控肿瘤侵袭和转移的信号通路，与患者的不良预后密切相关。本文旨在阐明HIF-1α和VEGF之间的相互作用和调节机制，以及在肿瘤侵袭和转移中可能的临床影响。</p><p>关键词 :缺氧诱导因子-1α，血管内皮生长因子，肿瘤</p><disp-formula id="hanspub.35655-formula44"><graphic xlink:href="//html.hanspub.org/file/19-1571309x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/19-1571309x8_hanspub.png" /> <img src="//html.hanspub.org/file/19-1571309x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>肿瘤严重威胁着公众健康。据报道2020年，中国的癌症病例将达到451万例左右，癌症死亡人数可能达到304万人 [<xref ref-type="bibr" rid="hanspub.35655-ref1">1</xref>]。可以预见今后很长一段时间，肿瘤都将是危害中国人健康的极其重要的问题之一。目前该病难治和复发的重要原因是肿瘤细胞的侵袭和转移。且肿瘤侵袭和转移的机制仍有待于进一步阐明，特别是当下靶向治疗所依赖的分子机制。不过有研究证实局部微环境缺氧在肿瘤进展过程中起着关键作用，主要通过缺氧/HIF-1α的驱动和VEGF的过表达及其受体的激活等机制促进肿瘤持续增殖、持续血管生成和局部侵袭、远处转移等 [<xref ref-type="bibr" rid="hanspub.35655-ref2">2</xref>]。本文现就HIF-1α/VEGF在肿瘤的侵袭和转移过程中的研究进展作一综述。</p></sec><sec id="s4"><title>2. HIF-1α概述</title><p>HIF-1α是一个120 kDa的氧依赖转录激活因子，在众多组织中普遍表达(包括肿瘤组织)。其与果蝇(PerandSim, PAS)具有高度同源性的两个亚单位的碱基–螺旋–环–螺旋(bHLH)基序证明它们都属于bHLH-PAS蛋白家族。除bHLH和PAS结构域外，还有两个反式激活结构域：N-末端的转录激活区(NTAD)和C-末端的转录激活区(CTAD)，及一个氧敏感的氧依赖性降解域(ODDD) [<xref ref-type="bibr" rid="hanspub.35655-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref5">5</xref>]。有多种机制参与HIF-1α分子的活性调节，但目前证实 [<xref ref-type="bibr" rid="hanspub.35655-ref6">6</xref>] 对HIF-1α活性影响最大的分子机制是由双加氧酶依赖的泛素-蛋白酶体途径介导的系统。位于HIF-1α的P402和P564的两个脯氨酸残基被称为PHD的双加氧酶(包括PHD1-3)脯氨酰羟化通过含有pVHL的E3泛素连接酶触发泛素化反应，通过半衰期为6~8分钟的泛素–蛋白酶体系统导致HIF-1α在常氧条件下的蛋白水解。而在缺氧微环境中，PHD活性下降，HIF-1α蓄积并移位到细胞核，与β亚单位二聚化，并与HIF-1α结合位点(HBS)结合，从而促进多种靶基因的转录，并调控靶基因表达。HIF-1α进而促进了一些缺氧诱导的细胞事件，如细胞增殖、迁移、侵袭、血管生成和细胞代谢 [<xref ref-type="bibr" rid="hanspub.35655-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref8">8</xref>]。</p></sec><sec id="s5"><title>3. VEGF概述</title><p>VEGF是1989年由Gospodarowicz [<xref ref-type="bibr" rid="hanspub.35655-ref9">9</xref>] 分离出的糖基化多肽性分泌因子，其编码基因位于第六号染色体短臂上，由8个外显子和7个内含子交替构成，总长约14 kb。VEGF家族在哺乳动物中表达包含VEGF-A，VEGF-B，VEGF-C，VEGF-D和胎盘生长因子(PLGF) 5个成员。不同成员之间功能具有差异性。VEGF-A即通常说的VEGF，是目前发现的调节血管生成的关键因子 [<xref ref-type="bibr" rid="hanspub.35655-ref10">10</xref>]，VEGF-B暂未发现其诱导血管生成和血管通透性的功能 [<xref ref-type="bibr" rid="hanspub.35655-ref11">11</xref>]，VEGF-C和VEGF-D与淋巴管生成密切相关 [<xref ref-type="bibr" rid="hanspub.35655-ref12">12</xref>]。VEGF的生物学效应是通过其亚型与不同的血管内皮细胞表面受体(VEGFR1、2、3)结合后进行信号转导而发挥。VEGF-A可选择性地结合VEGFR-1及VEGFR-2，通过血管生成途径，在肿瘤生长、区域浸润和淋巴转移中起重要作用 [<xref ref-type="bibr" rid="hanspub.35655-ref10">10</xref>]。VEGF-C和VEGF-D通过与淋巴管内皮细胞表面VEGFR-3结合，调控淋巴管生成，在胃癌肿瘤细胞淋巴管侵袭和淋巴结的转移中有重要作用 [<xref ref-type="bibr" rid="hanspub.35655-ref12">12</xref>]。VEGF还可诱导分泌多种血浆酶原激活物和金属蛋白酶，促进血管生成，为肿瘤浸润及转移提供条件 [<xref ref-type="bibr" rid="hanspub.35655-ref13">13</xref>]。</p></sec><sec id="s6"><title>4. HIF-1α和VEGF促进肿瘤血管生成</title><p>积累表明在肿瘤生长和转移过程中，由于肿瘤细胞的疯狂增殖，无法及时建立血管网，造成肿瘤细胞生长处于缺氧且酸性物质积聚的微环境中。而肿瘤实质微环境的特点，以及无氧状态诱导一系列参与血管生成和无氧代谢的基因表达，可以帮助肿瘤细胞更好地适应无氧环境，并更容易形成侵袭和转移能力 [<xref ref-type="bibr" rid="hanspub.35655-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref16">16</xref>]。这一过程与新生血管形成密切相关，新生血管可为肿瘤细胞快速生长提供条件，进而加速实体肿瘤的发生、侵袭和转移 [<xref ref-type="bibr" rid="hanspub.35655-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref18">18</xref>]。有报道表明，通过微血管密度这一肿瘤血管生成最主要的量化指标，可预测肿瘤浸润和转移程度 [<xref ref-type="bibr" rid="hanspub.35655-ref19">19</xref>]。而且研究已证实缺氧条件下，HIF-1α被激活并调控VEGF等转录因子参与肿瘤新血管生成 [<xref ref-type="bibr" rid="hanspub.35655-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref22">22</xref>]。其机制可能是在缺氧驱动的血管生成中，缺氧激活PI3K/AKT通路，阻止HIF-1α翻译后羟基化和随后的HIF-1α的降解，使其积聚，然后转移到细胞核，并形成转录起始复合物，启动靶基因转录，导致相应的蛋白产物增加，包括VEGF的表达增强，从而促进肿瘤血管生成 [<xref ref-type="bibr" rid="hanspub.35655-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref39">39</xref>]。Yokoe [<xref ref-type="bibr" rid="hanspub.35655-ref24">24</xref>] 等研究也表明在缺氧时，HIF-1α可以逃避pVHL的识别，从而稳定存在于缺氧环境中。并通过PI3K途径和缺氧激活的PI3K/Akt/mTOR途径调节VEGF蛋白的合成 [<xref ref-type="bibr" rid="hanspub.35655-ref25">25</xref>]。Palazon等 [<xref ref-type="bibr" rid="hanspub.35655-ref26">26</xref>] 还证实，HIF-1α磷酸化后也可诱导VEGF靶基因的转录。而VEGF的过表达，主要通过受体VEGFR-1和VEGFR-2发挥作用，当VEGF与其受体结合后激活信号转导，导致内皮细胞增殖、迁移和新生血管形成。新生血管可以为肿瘤提供营养、氧气，排出代谢废物，并刺激肿瘤生长，加速肿瘤转移 [<xref ref-type="bibr" rid="hanspub.35655-ref10">10</xref>]。因此，联合应用抗血管生成药物和HIF-1α抑制剂可能是有效的，因为抗血管生成药物会切断肿瘤的血液供应，而HIF-1α抑制剂可以增强抗血管生成药物的作用，降低耐药的可能性 [<xref ref-type="bibr" rid="hanspub.35655-ref42">42</xref>]。</p></sec><sec id="s7"><title>5. HIF-1α、VEGF参与肿瘤的侵袭和转移</title><p>肿瘤的侵袭和转移是影响患者预后的主要危险因素，它是一个不受控制的细胞增殖、血管生成、分离、运动、侵入血流、沉积在微血管中，最后从血管外渗并在次级部位增殖的连续事件。这一过程复杂，机制不明确，涉及到了多个基因和信号通路，而且目前关于这方面的靶向治疗仍未取得突破性进展 [<xref ref-type="bibr" rid="hanspub.35655-ref27">27</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref28">28</xref>]。如用于治疗转移性肾细胞癌(mRCC)的5种抗VEGF/VEGFR药物，尽管患者的无进展生存率和有效率有所提高，但均未能显著提高患者的生存率 [<xref ref-type="bibr" rid="hanspub.35655-ref29">29</xref>]。因此研究肿瘤的侵袭和转移机制，对于探索新的治疗靶点和治疗机制，提高肿瘤患者的治疗效果和预后具有重要意义。HIF-1α与VEGF由于其在调节肿瘤血管生成从而促进肿瘤生长、侵袭和转移中的巨大作用早已被人们所熟知并关注。并期待以此开发出在肿瘤的治疗中有更好效果的药物。</p><p>多项研究表明高表达的HIF-1α预示着更高的TNM分期，远处转移和血管侵犯，以及阳性淋巴结 [<xref ref-type="bibr" rid="hanspub.35655-ref30">30</xref>]。这些现象是可以理解的，因为增加的HIF-1α可激活磷脂酰肌醇-3激酶/蛋白激酶B (PI3K/AKT)和人鞘氨醇激酶-1/1-磷酸鞘氨醇(SphK1/S1P)信号通路，介导瘤体内新生血管的形成，增强肿瘤细胞的活动能力，从而促进肿瘤的进展 [<xref ref-type="bibr" rid="hanspub.35655-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref32">32</xref>]。而且HIF-1α还可通过激活Wnt、TGF-β/Smad3或Wnt、Notch、TGF-β等多条信号转导通路调控其关键转录因子表达，诱导上皮间质转化效应，进而促进肿瘤浸润转移 [<xref ref-type="bibr" rid="hanspub.35655-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref34">34</xref>]。甚至HIF-1α通过刺激肿瘤细胞或肿瘤浸润免疫相关细胞中的PD-L1表达促进肿瘤细胞免疫逃逸 [<xref ref-type="bibr" rid="hanspub.35655-ref35">35</xref>]。不过，更多HIF-1α调节肿瘤转移的机制仍有待进一步阐明。同样Zhao等 [<xref ref-type="bibr" rid="hanspub.35655-ref36">36</xref>] 发现VEGF的表达与肿瘤侵袭能力呈明显正相关，VEGF表达越高，促血管生成的作用也越显著，肿瘤的浸润和转移也越早。通过干预VEGF的生成或阻断VEGF与其受体的结合则可抑制肿瘤的血管生成，从而抑制肿瘤的生长、浸润和转移。Liu等 [<xref ref-type="bibr" rid="hanspub.35655-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref38">38</xref>] [<xref ref-type="bibr" rid="hanspub.35655-ref39">39</xref>] 发现用siRNA敲除人结直肠癌(CRC)细胞系中的VEGF后，肿瘤细胞的生长被极大地抑制，从而显著的抑制了结直肠癌的迁移和侵袭。并阐述了该现象产生的机制：这一现象不是通过已有的旁分泌或自分泌VEGF信号的抑制。而是通过调节结直肠癌细胞中多受体酪氨酸激酶(RTK；例如EGFR和cMET)和下游AKT信号的活性介导的。</p><p>然而，HIF-1α/VEGF的调控机制不单单止于此。近来研究还发现缺氧/HIF-1α可直接或间接(后者通过腺苷、乳酸或酸中毒)促进VEGF的表达及激活其受体，从而促进肿瘤逃避免疫监视 [<xref ref-type="bibr" rid="hanspub.35655-ref40">40</xref>]。同时HIF-1α可通过VEGF和血小板衍生生长因子参与血管生成的调节，增强Notch信号的转录活性，介导肿瘤代谢途径(葡萄糖、脂质和氨基酸代谢)，并通过免疫抑制发挥肿瘤促进作用 [<xref ref-type="bibr" rid="hanspub.35655-ref41">41</xref>]。这些研究为通过HIF-1α/VEGF通路治疗肿瘤获得更好的效果提供了可能。在研究光动力疗法(PDT)时 [<xref ref-type="bibr" rid="hanspub.35655-ref42">42</xref>] 发现，PDT的治疗效果通常被肿瘤血管生成所掩盖。其机制是：PDT后PAK1表达上调并防止HIF-1α蛋白在泛素介导下降解，因此造成HIF-1α蛋白积累并转运到细胞核与VEGF启动子结合，从而上调VEGF的表达，促进肿瘤血管生成。不过当敲除PAK1基因后，这些现象被逆转，促进HIF-1α降解，最终抑制肿瘤血管生成。因此，通过敲除PAK1以抑制HIF-1α/VEGF的抗血管生成疗法，将可能为PDT联合治疗提供一个新思路。</p><p>综上所述：HIF-1α和VEGF可以成为人们研究肿瘤侵袭和转移机制的一个突破口，并可能由此开发出更有效的肿瘤治疗药物，从而提高肿瘤的治疗水平。</p></sec><sec id="s8"><title>6. 展望</title><p>肿瘤的侵袭和转移过程涉及众多生长因子、细胞因子、信号级联反应和细胞过程，使得开发出更加有效的靶向药成为一项挑战。不过HIF-1α/VEGF通路是非常值得探索的一个环节。而且我们相信随着研究的越来越深入，在不久的将来以HIF-1α和VEGF为治疗靶点的靶向治疗在肿瘤治疗中会越来越成功，并带给肿瘤患者新的希望。</p></sec><sec id="s9"><title>文章引用</title><p>崔昌裕,赵 红. HIF-1α、VEGF与肿瘤的侵袭和转移HIF-1α, VEGF and Tumor Invasion and Metastasis[J]. 临床医学进展, 2020, 10(05): 811-816. https://doi.org/10.12677/ACM.2020.105124</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35655-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">(2018) Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon.  
&lt;br&gt;https://gco.iarc.fr/today</mixed-citation></ref><ref id="hanspub.35655-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Vaupel, P. and Multhoff, G. (2020) Fatal Alliance of Hypoxia-/HIF-1α-Driven Microenvironmental Traits Promoting Cancer Progression. Advances in Experimental Medicine and Biology, 1232, 169-176.  
&lt;br&gt;https://doi.org/10.1007/978-3-030-34461-0_21</mixed-citation></ref><ref id="hanspub.35655-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Masoud, G.N. and Li, W. (2015) HIF-1α Pathway: Role, Regulation and Intervention for Cancer Therapy. Acta Pharmaceutica Sinica B, 5, 378-389. &lt;br&gt;https://doi.org/10.1016/j.apsb.2015.05.007</mixed-citation></ref><ref id="hanspub.35655-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Albadari, N., Deng, S.S. and Li, W. (2019) The Transcriptional Factors HIF-1 and HIF-2 and Their Novel Inhibitors in Cancer Therapy. Expert Opinion on Drug Discovery, 14, 667-682. &lt;br&gt;https://doi.org/10.1080/17460441.2019.1613370</mixed-citation></ref><ref id="hanspub.35655-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fu, J.-D., Yao, J.-J., Wang, H., Cui, W.-G., Leng, J., Ding, L.-Y. and Fan, K.-Y. (2019) Effects of EGCG on Proliferation and Apoptosis of Gastric Cancer SGC7901 Cells via Down-Regulation of HIF-1α and VEGF under a Hypoxic State. European Review for Medical and Pharmacological Sciences, 23, 155-161.</mixed-citation></ref><ref id="hanspub.35655-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sho, K., Minoru, K., Yoko, G., et al. (2018) Regulatory Mechanisms of Hypoxia-Inducible Factor 1 Activity: Two Decades of Knowledge. Cancer Sciences, 109, 560-571. &lt;br&gt;https://doi.org/10.1111/cas.13483</mixed-citation></ref><ref id="hanspub.35655-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">LaGory, E.L. and Giaccia, A.J. (2016) The Ever-Expanding Role of HIF in Tumour and Stromal Biology. Nature Cell Biology, 18, 356-365. &lt;br&gt;https://doi.org/10.1038/ncb3330</mixed-citation></ref><ref id="hanspub.35655-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Aditi, N., Dhar, R.A., Niranjan, R., et al. (2020) HIF1α-Dependent Upregulation of ATAD2 Promotes Proliferation and Migration of Stomach Cancer Cells in Response to Hypoxia. Biochemical and Biophysical Research Communications, 523, 916-923. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2019.12.130</mixed-citation></ref><ref id="hanspub.35655-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gospodarowicz, D., Abraham, J.A. and Schilling, J. (1989) Isolation and Characterization of a Vascular Endothelial Cell Mitogen Produced by Pituitary-Derived Folliculo Stellate Cells. Proceedings of the National Academy of Sciences of the United States of America, 86, 7311-7315. &lt;br&gt;https://doi.org/10.1073/pnas.86.19.7311</mixed-citation></ref><ref id="hanspub.35655-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yang Tai, Gao, J.H., Wen, S.L., Tong, H., Huang, Z.Y. and Tang, C.-W. (2016) Su2010 Correlations between VEGF-A Expression and Prognosis in Patients with Gastric Adenocarcinoma. Gastroenterology, 150, S610.  
&lt;br&gt;https://doi.org/10.1016/S0016-5085(16)32092-3</mixed-citation></ref><ref id="hanspub.35655-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">徐越明, 童玥, 姚文兵. 血管内皮生长因子B研究进展[J]. 药学进展, 2017, 41(6): 458-464.  
&lt;br&gt;https://doi.org/10.1007/s11623-017-0811-2</mixed-citation></ref><ref id="hanspub.35655-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Macedo, F., Ladeira, K., Longatto-Filho, A. and Martins, S.F. (2017) Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission? Journal of Gastric Cancer, 17, 1.  
&lt;br&gt;https://doi.org/10.5230/jgc.2017.17.e1</mixed-citation></ref><ref id="hanspub.35655-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">闻哲, 张霓霓, 黄桂林. 血管生成相关因子在口腔鳞癌中的研究进展[J]. 中国医药导报, 2016, 13(31): 57-60.</mixed-citation></ref><ref id="hanspub.35655-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Huang, Y.Q., Lin, D. and Taniguchi, C.M. (2017) Hypoxia Inducible Factor (HIF) in the Tumor Microenvironment: Friend or Foe? Science China Life Sciences, 60(10). &lt;br&gt;https://doi.org/10.1007/s11427-017-9178-y</mixed-citation></ref><ref id="hanspub.35655-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Martin, J.D., Fukumura, D., Duda, D.G., Boucher, Y. and Jain, R.K. (2016) Corrigendum: Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity. Cold Spring Harbor Perspectives in Medicine, 6, a027094. &lt;br&gt;https://doi.org/10.1101/cshperspect.a031195</mixed-citation></ref><ref id="hanspub.35655-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Ou, X.-W., Wang, R.-X., Kang, M.-F., et al. (2018) Hypoxia Promotes Migration and Invasion of Gastric Cancer Cells by Activating HIF-1α and Inhibiting NDRG2 Associated Signaling Pathway. European Review for Medical and Pharmacological Sciences, 22, 8237-8247.</mixed-citation></ref><ref id="hanspub.35655-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J.J., Xu, J., Dong, Y.H. and Huang, B. (2018) Down-Regulation of HIF-1α Inhibits the Proliferation, Migration, and Invasion of Gastric Cancer by Inhibiting PI3K/AKT Pathway and VEGF Expression. Bioscience Reports, 38, Article No.: BSR20180741. &lt;br&gt;https://doi.org/10.1042/BSR20180741</mixed-citation></ref><ref id="hanspub.35655-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Macedo, F., Ladeira, K., Longatto-Filho, A., et al. (2017) Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission? Journal of Gastric Cancer, 17, 1-10.  
&lt;br&gt;https://doi.org/10.5230/jgc.2017.17.e1</mixed-citation></ref><ref id="hanspub.35655-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Felix, A.S., Lenz, P., Pfeiffer, R.M., et al. (2016) Relationships between Mammographic Density, Tissue Microvessel Density, and Breast Biopsy Diagnosis. Breast Cancer Research, 18, 88. &lt;br&gt;https://doi.org/10.1186/s13058-016-0746-9</mixed-citation></ref><ref id="hanspub.35655-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Mahase, S., Rattenni, R.N., Wesseling, P., Leenders, W., Baldotto, C., Jain, R. and Zagzag, D. (2017) Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas. The American Journal of Pathology, 187(5). &lt;br&gt;https://doi.org/10.1016/j.ajpath.2017.01.010</mixed-citation></ref><ref id="hanspub.35655-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J.-C., Li, G.-Y., Li, P.-P., et al. (2017) Suppression of Hypoxia-Induced Excessive Angiogenesis by Metformin via Elevating Tumor Blood Perfusion. Oncotarget, 8, 73892-73904.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.18029</mixed-citation></ref><ref id="hanspub.35655-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Aneese, A.M., Manuballa, V., Amin, M., et al. (2017) Bladder Urothelial Carcinoma Extending to Rectal Mucosa and Presenting with Rectal Bleeding. World Journal of Gastrointestinal Endoscopy, 9, 282.  
&lt;br&gt;https://doi.org/10.4253/wjge.v9.i6.282</mixed-citation></ref><ref id="hanspub.35655-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">曹辉琼, 蔡清红. 缺氧诱导因子-1α及血管内皮生长因子的表达与胃癌血管生成的关系[J]. 吉林医学, 2020, 41(1): 184-185.</mixed-citation></ref><ref id="hanspub.35655-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Shunichi, Y., Takatoshi, N., Yuichi, K., Kazuhide, H. and Michio, A. (2015) Indomethacin-Induced Intestinal Epithelial Cell Damage Is Mediated by pVHL Activation through the Degradation of Collagen I and HIF-1α. Biochemical and Biophysical Research Communications, 468, 671-676. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2015.11.014</mixed-citation></ref><ref id="hanspub.35655-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Jayant, D., Shweta, K., Kumar, R.S., et al. (2018) Centchroman Regulates Breast Cancer Angiogenesis via Inhibition of HIF-1α/VEGFR2 Signalling Axis. Life Sciences, 193, 9-19. &lt;br&gt;https://doi.org/10.1016/j.lfs.2017.11.045</mixed-citation></ref><ref id="hanspub.35655-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Vojnovic, N., Loman, N., Goldrath, A.W., et al. (2017) An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell, 32, 669.e5-683.e5. &lt;br&gt;https://doi.org/10.1016/j.ccell.2017.10.003</mixed-citation></ref><ref id="hanspub.35655-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Joseph, J.P., Harishankar, M.K., Pillai, A.A. and Devi, A. (2018) Hypoxia Induced EMT: A Review on the Mechanism of Tumor Progression and Metastasis in OSCC. Oral Oncology, 80, 23-32.  
&lt;br&gt;https://doi.org/10.1016/j.oraloncology.2018.03.004</mixed-citation></ref><ref id="hanspub.35655-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Tam, S.Y., Wu, V.W.C. and Law, H.K.W. (2020) Hypoxia-Induced Epithelial-Mesenchymal Transition in Cancers: HIF-1α and Beyond. Frontiers in Oncology, 10, 486. &lt;br&gt;https://doi.org/10.3389/fonc.2020.00486</mixed-citation></ref><ref id="hanspub.35655-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Iacovelli, R., Sternberg, C.N., Porta, C., et al. (2015) Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer: A Systematic Review and Meta-Analysis. Current Drug Targets, 16, 164-170.  
&lt;br&gt;https://doi.org/10.2174/1389450115666141120120145</mixed-citation></ref><ref id="hanspub.35655-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Tátrai, E., Bartal, A., Gacs, A., et al. (2017) Cell Type-Dependent HIF1α-Mediated Effects of Hypoxia on Proliferation, Migration and Metastatic Potential of Human Tumor Cells. Oncotarget, 8, 44498-44510.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.17806</mixed-citation></ref><ref id="hanspub.35655-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">周晓黎, 舒磊, 廖艳, 石拓, 梅智谋, 杨家耀, 时昭红. PI3K/AKT通路在低氧环境下对结肠癌细胞HIF-1α及糖酵解的作用[J]. 华中科技大学学报(医学版), 2018, 47(2): 203-206.</mixed-citation></ref><ref id="hanspub.35655-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Ader, I., Gstalder, C., Bouquerel, P., et al. (2015) Neutralizing S1P Inhibits Intratumoral Hypoxia, Induces Vascular Remodelling and Sensitizes to Chemotherapy in Prostate Cancer. Oncotarget, 6, 13803-13821.  
&lt;br&gt;https://doi.org/10.18632/oncotarget.3144</mixed-citation></ref><ref id="hanspub.35655-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Yeh, Y.H., Wang, S.W., Yeh, Y.C., et al. (2016) Rhapontigenin Inhibits TGF-β-Mediated Epithelial Mesenchymal Transition via the PI3K/AKT/m TOR Pathway and Is Not Associated with HIF-1α Degradation. Oncology Reports, 35, 2887-2895. &lt;br&gt;https://doi.org/10.3892/or.2016.4664</mixed-citation></ref><ref id="hanspub.35655-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Liu, L. and Xiao, W. (2017) Notch1 Signaling Induces Epithelial-Mesenchymal Transition in Lens Epithelium Cells during Hypoxia. BMC Ophthalmology, 17, 135. &lt;br&gt;https://doi.org/10.1186/s12886-017-0532-1</mixed-citation></ref><ref id="hanspub.35655-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Pinato, D.J., Black, J.R., Trousil, S., Dina, R.E., Trivedi, P., Mauri, F.A. and Sharma, R. (2017) Programmed Cell Death Ligands Expression in Phaeochromocytomas and Paragangliomas: Relationship with the Hypoxic Response, Immune Evasion and Malignant Behavior. OncoImmunology, 6, e1358332.  
&lt;br&gt;https://doi.org/10.1080/2162402X.2017.1358332</mixed-citation></ref><ref id="hanspub.35655-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Z., Li, Y.K., Shukla, R., Liu, H., Jain, A., Barve, A. and Cheng, K. (2019) Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. Theranostics, 9, 4508-4524.  
&lt;br&gt;https://doi.org/10.7150/thno.34314</mixed-citation></ref><ref id="hanspub.35655-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Bhattacharya, R., Fan, F., Wang, R., et al. (2017) Intracrine VEGF Signalling Mediates Colorectal cancer cell Migration and Invasion. British Journal of Cancer, 117, 848-855. &lt;br&gt;https://doi.org/10.1038/bjc.2017.238</mixed-citation></ref><ref id="hanspub.35655-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Bhattacharya, R., Ye, X.-C., Wang, R., Ling, X., McManus, M., Fan, F., Boulbes, D. and Ellis, L.M. (2016) Intracrine VEGF Signaling Mediates the Activity of Prosurvival Pathways in Human Colorectal Cancer Cells. Cancer Research, 76, 3015-3026 &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-15-1605</mixed-citation></ref><ref id="hanspub.35655-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Ridiandries, A., Tan, J.T. and Bursill, C.A. (2016) The Role of CC-Chemokines in the Regulation of Angiogenesis. Int J Mol Sci., 17(11). &lt;br&gt;https://doi.org/10.3390/ijms17111856</mixed-citation></ref><ref id="hanspub.35655-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Lutske, L., van Diest, P., van der Groep, P., et al. (2017) Expression of HIF-1α in Medullary Thyroid Cancer Identifies a Subgroup with Poor Prognosis. Oncotarget, 8, 28650-28659. &lt;br&gt;https://doi.org/10.18632/oncotarget.15622</mixed-citation></ref><ref id="hanspub.35655-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Veli, B., Kemal, D., Oktay, B., et al. (2015) Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab. Asian Pacific Organization for Cancer Prevention, 16, 6149-6154. &lt;br&gt;https://doi.org/10.7314/APJCP.2015.16.14.6149</mixed-citation></ref><ref id="hanspub.35655-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, S., Gao, Y., Yu, Q.H., Li, M., Cheng, X., Hu, S.B., Song, Z.F. and Zheng, Q.C. (2020) P-21-Activated Kinase 1 Contributes to Tumor Angiogenesis upon Photodynamic Therapy via the HIF-1α/VEGF Pathway. Biochemical and Biophysical Research Communications, 526, 98-104. &lt;br&gt;https://doi.org/10.1016/j.bbrc.2020.03.054</mixed-citation></ref></ref-list></back></article>